All In Biotech

Drug Trial Radar · NCT05631574

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)

Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

13

Actual

Start

Jan 12, 2023

Primary completion

Jan 15, 2025

Study completion Jan 15, 2025

Sponsor

Lead sponsor
Biomea Fusion Inc.Industry
Sponsor type
Industry
First posted
Nov 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).

Conditions

  • Non Small Cell Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • NSCLC
  • PDAC
  • CRC
  • Relapsed Cancer
  • Refractory Cancer
  • Stage III Pancreatic Cancer
  • Stage IV Pancreatic Cancer
  • Stage III Non-small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer
  • Stage III Colorectal Cancer
  • Stage IV Colorectal Cancer
  • Stage III NSCLC
  • Stage IV NSCLC
  • KRAS Mutation-Related Tumors

Interventions

  • BMF-219Drug

    BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.Time frame: 30 months
  2. To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.Time frame: 30 months

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Cancer Treatment Centers of America - Phoenix

    Goodyear, Arizona

  • California Cancer Associates for Research and Excellence (cCARE)

    Encinitas, California

  • University of California, San Diego

    La Jolla, California

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Cancer Treatment Centers of America - Atlanta

    Atlanta, Georgia

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern Univeristy

    Chicago, Illinois

  • Cancer Treatment Centers of America - Chicago

    Zion, Illinois

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Ohio State University

    Columbus, Ohio

  • Tennessee Oncology

    Nashville, Tennessee

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • NEXT Oncology

    San Antonio, Texas

  • NEXT Virginia

    Fairfax, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital Yonsei University Health System - PPDS

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.